Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

Have you noticed the side effects listed for one of those new drugs being advertised on TV? It may seem as if one of those marvelous medicines might be a good solution for your problem, but the long ...

Have you noticed the side effects listed for one of those new drugs being advertised on TV? It may seem as if one of those marvelous medicines might be a good solution for your problem, but the long ...

Eli Lilly has spent months signaling it would challenge Novo Nordisk’s oral GLP-1 franchise. Now it has data to back that up.

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

Novo Nordisk reported a loss in a head-to-head trial of CagriSema against Lilly’s Zepbound earlier this week. This time around, Lilly's orforglipron bested Novo's oral semaglutide in blood sugar ...

Once-daily orforglipron induced greater reductions in HbA1c and body weight than once-daily oral semaglutide for adults with type 2 diabetes, according to data from the ACHIEVE-3 trial published in ...

Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment discontinuations than Novo ...

Carey, nominated in 2024 and 2025, has had 19 No. 1 hits on the Billboard Hot 100, while soul-jazz vocalist Sade, also ...

Vivtex Corporation, launched in 2018 as a spinoff of the Massachusetts Institute of Technology (MIT), will license oral drug-delivery technologies to Novo for weight loss, diabetes, and related ...

The potentially $2.1 billion collaboration gives Novo access to technologies that are meant to help optimize the delivery of ...

Novo Nordisk is slashing the list prices of its flagship weight-loss and diabetes drugs, including Wegovy and Ozempic, by up ...